Study of the Week: Investigational Treatment Shows Promise for Treating Nonalcoholic Steatohepatitis
source: pixabay.com

Study of the Week: Investigational Treatment Shows Promise for Treating Nonalcoholic Steatohepatitis

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Investigational Treatment Shows Promise for Treating Nonalcoholic Steatohepatitis
Dupilumab Reduces Type 2 Inflammation in People Living with COPD, Study Shares
source: shutterstock.com

Dupilumab Reduces Type 2 Inflammation in People Living with COPD, Study Shares

  The World Health Organization (WHO) reports that an estimated 3.23 million people worldwide die each year from chronic obstructive pulmonary disease (COPD), making it the third leading cause of…

Continue Reading Dupilumab Reduces Type 2 Inflammation in People Living with COPD, Study Shares
These Clinical Trials Could be Game Changers in the Latter Half of 2023
source: shutterstock.com

These Clinical Trials Could be Game Changers in the Latter Half of 2023

In a story from BioPharma Dive, a number of high-profile clinical trials are under way that could see conclusive results by the end of 2023. While some of these are…

Continue Reading These Clinical Trials Could be Game Changers in the Latter Half of 2023
Study Found Ziritaxestat Ineffective in Improving IPF Lung Function
source: pixabay.com

Study Found Ziritaxestat Ineffective in Improving IPF Lung Function

Both Ofev (nintedanib) and Esbriet (pirfenidone) are FDA-approved to treat individuals living with mild, moderate, or severe idiopathic pulmonary fibrosis (IPF). The treatments work by preventing fibrosis (scarring) and stopping…

Continue Reading Study Found Ziritaxestat Ineffective in Improving IPF Lung Function
A Top FDA Official Overrules Reviewers’ Rejection of Sarepta’s DMD Gene Therapy
source: shutterstock.com

A Top FDA Official Overrules Reviewers’ Rejection of Sarepta’s DMD Gene Therapy

  It looked as if the fate of Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy was pretty much sealed until an FDA official intervened. This information was provided by…

Continue Reading A Top FDA Official Overrules Reviewers’ Rejection of Sarepta’s DMD Gene Therapy
Her Family Thought She Was Struggling with Mental Health. It Was Anti-NMDA Receptor Encephalitis.
95C / Pixabay

Her Family Thought She Was Struggling with Mental Health. It Was Anti-NMDA Receptor Encephalitis.

As she stood in the garden, surrounded by friends and family, a splitting headache richocheted through Ciara Wilkie's head. Her vision blurred. At first, Ciara didn't think much of it.…

Continue Reading Her Family Thought She Was Struggling with Mental Health. It Was Anti-NMDA Receptor Encephalitis.